首页> 外文期刊>Cellular and Molecular Neurobiology >Study on the proliferation and drug-resistance of human brain tumor stem-like cells.
【24h】

Study on the proliferation and drug-resistance of human brain tumor stem-like cells.

机译:人脑肿瘤干样细胞的增殖和耐药性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Brain tumor stem-like cells (BTSLCs) have been implied to play an important role in genesis and development of glioma. However, their characteristics on proliferation and drug-resistance are uncertain thoroughly. In this experiment, some of the biological characteristics about BTSLCs were explored. Twenty cases of different grades of human glioma tissues were obtained from clinic. The primary glioma cells were collected and CD133(+) cells from them were purified by magnetic cell sorting assay. The BTSLCs were identified by testing the expression of CD133, Nestin, NSE, and GFAP, along with the culture process. WST-8 assay kit was used to evaluate the proliferating situation of CD133(+) cells in the different grade gliomas, and to compare the drug-resistance between the CD133(+) and CD133( - ) cells in the medium containing different concentrations of teniposide (VM-26). The results showed that the CD133(+) cells could regenerate by self-renewal, then generate and different into NSE(+) and GFAP(+) cells, respectively. CD133(+) cells in the high grade of gliomas showed the faster generation than the ones in the low grade. The number of survived CD133(+) cells in the medium containing VM-26 was much more than the CD133(-) ones in it. Therefore, it was implied that the CD133(+) BTSLCs existed in the glioma tissues possessed the more tolerant ability to the VM-26, and could proliferate much more easily in the high-grade glioma.
机译:已经暗示脑肿瘤干样细胞(BTSLC)在神经胶质瘤的发生和发展中起重要作用。但是,它们在增殖和抗药性方面的特征尚不确定。在此实验中,探索了有关BTSLC的一些生物学特性。从诊所获得了20例不同等级的人类神经胶质瘤组织。收集原发性神经胶质瘤细胞,并通过磁性细胞分选测定法纯化其中的CD133(+)细胞。通过测试CD133,Nestin,NSE和GFAP的表达以及培养过程来鉴定BTSLC。 WST-8分析试剂盒用于评估不同等级神经胶质瘤中CD133(+)细胞的增殖情况,并比较CD133(+)和CD133(-)细胞在含有不同浓度脑胶质瘤的培养基中的耐药性Teniposide(VM-26)。结果表明,CD133(+)细胞可以通过自我更新进行再生,然后分别生成并分化为NSE(+)和GFAP(+)细胞。高等级神经胶质瘤中的CD133(+)细胞显示出比低等级神经胶质瘤中的更快。包含VM-26的培养基中存活的CD133(+)细胞数量远大于其中的CD133(-)细胞。因此,这表明存在于神经胶质瘤组织中的CD133(+)BTSLCs对VM-26具有更强的耐受能力,并且在高级别神经胶质瘤中更容易增殖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号